Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Jared Gollob, M.D. resigned as Chief Medical Officer effective July 27, 2026.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jared Gollob, M.D. resigned as Chief Medical Officer effective July 27, 2026
- Continued advisor role through December 31, 2026 supports transition continuity
- Terence Rooney, M.D. appointed successor CMO effective July 27, 2026
- Departure attributed to personal reasons, with no reported disagreement over company practices or policies
Item 7.01 · Regulation FD Disclosure
- Dr. Rooney appointed Chief Medical Officer, changing Kymera’s clinical leadership
- Dr. Gollob’s retirement creates a senior medical leadership transition
- Appointment and retirement details furnished in Exhibit 99.1 for investor review
Item EX-99.1 · Exhibit EX-99.1
- Terence Rooney appointed Chief Medical Officer to lead global clinical development and Kymera’s oral immunology portfolio
- Rooney brings immunology development experience from Johnson & Johnson, Eli Lilly and Roche
- Jared Gollob retiring after eight years, remaining as advisor through year-end
- Leadership transition places execution of multiple clinical programs under a new development chief
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.